Clinical Research Directory

Inclusion Criteria: To participate in the study, all the following inclusion criteria must be met: * Patients aged 18 years or older * Written informed consent obtained before participating in the study. * Patient is willing and able to complete the assessments, including PRO questionnaires, as outlined in this study. * Diagnosis of RMS per McDonald Criteria (2017) occurred prior to initiation of Ofatumumab. * Treatment with Ofatumumab is in accordance with the Portuguese indication of Kesimpta® (i.e., treatment of adult patients with relapsing multiple sclerosis (RMS) with active disease defined by clinical or imaging features). * Patients that have initiated Ofatumumab up to 12 M prior inclusion in the study OR Patients that are initiating Ofatumumab at the moment of study inclusion. Exclusion Criteria: To participate in the study, none of the following exclusion criteria must be met: * Use of investigational drugs during the study, OR between Ofatumumab initiation and inclusion into the study, OR within 5 half-lives of investigational drug before Ofatumumab initiation, OR until the expected pharmacodynamic effect has returned to baseline, whichever is longer. * Use of high efficacy therapy (including Ocrelizumab, Natalizumab, Mitoxantrone, Rituximab and Alemtuzumab) in both cohorts prior to the initiation of Ofatumumab.